Their possible application in AA warrants a full discussion of their practical considerations and points of therapeutic attack. Singri et al., 2002; P. Singri, D.P. West, K.B. Gordon. Biologic therapy for psoriasis: The new therapeutic frontier. Although non-biological therapies, including methotrexate and ciclosporin, show significant efficacy their side effect profiles have precluded their long term use for moderate to severe psoriasis. This review concentrates on new biological agents, focusing on the three agents approved for psoriasis within the past 18 months (alefacept, efalizumab, and etanercept). Biologic therapy for psoriasis: the new therapeutic frontier. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Presented at the European League Against Rheumatism 1215 June 2002. The biologics are the newest and most effective therapeutic weapon in the treatment of moderate-to-severe psoriasis and psoriatic arthritis that can significantly alter the course of the disease in a relatively short period of time. Real world experience with this class of drugs is expanding and more new biologics are becoming available. J Am Acad Dermatol 46(1):1-23 (2002 Jan). Singri P, West D, Gordon K. Biologic therapy for psoriasis: the new therapeutic frontier. Gordon KB, Langley RG, Leonardi C, et al.
Singri PWest DPGordon KB Biologic therapy for psoriasis: the new therapeutic frontier. Our medical picture shows the case of a 60 year old Caucasian male with a long term history of psoriasis. He had psoriatic involvement of the skin throughout his body. Singri P, West DP, Gordon KB (2002) Biologic therapy for psoriasis the new therapeutic frontier. Arch Dermatol 138: 657-663.